A high-tech company recently opened a new vaccine production platform in the Lin-gang Special Area, located in East China's Shanghai.

Maxvax Biology Technology Co Ltd is a Chengdu-based biopharmaceutical company that undertakes research and development, production and commercialization of innovative vaccines and new adjuvants.

It launched the new vaccine production platform in the Lingang Life Science & Tech Park in the Lin-gang Special Area on April 18.

Established in 2016 in Chengdu city, in Southwest China's Sichuan province, Maxvax Biology focuses on the industrialization of innovative human vaccines. The new vaccine production platform project covers an area of over 12,000 square meters with an annual production capacity of 30 million doses.

Additionally, the Lin-gang Phase I factory for Maxvax Biology is currently under construction, on a site covering about 50 mu (about 33,333 sq m). It will have several independent production lines, including those producing recombinant engineering bacteria, engineering cell protein vaccines and attenuated live vaccines.

The plant is expected to be completed and start operating in June 2024, with an annual vaccine production capacity exceeding 100 million doses that can meet the commercial production needs of four to six vaccine products.

An opening ceremony is held on April 18 for Maxvax Biology's vaccine production platform in the Lingang Life Science & Tech Park. [Photo/WeChat ID: shlgguanweihui]